Back to results
US 2026/0308163 A1Published application
Crystalline forms of a parp1 inhibitor
AssigneeGilead Sciences, Inc.
InventorsJing Liu, Jayachandra P. Reddy, Stefani Kocevska
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to salts and solid forms of a compound that are inhibitors of PARP and their uses as therapeutic agents for treating diseases, such as cancer.
Claims12
A crystalline form of Compound I:
- (Compound I Form I), wherein Compound I Form I is characterized by an X-ray powder diffractogram comprising peaks (±0.2°) at 8.1, 9.4, and 19.7 °2θ as determined on a diffractometer using Cu-Kα radiation.
A crystalline form of Compound I:
- (Compound I Form II), wherein Compound I Form II is characterized by an X-ray powder diffractogram comprising peaks (±0.2°) at 6.4, 9.1, and 18.7 °2θ as determined on a diffractometer using Cu-Kα radiation.
A crystalline form of Compound I:
- (Compound I Form III), wherein Compound I Form III is characterized by an X-ray powder diffractogram comprising peaks (±0.2°) at 4.7, 9.5, and 12.6 °2θ as determined on a diffractometer using Cu-Kα radiation.
7-76. (canceled)
Dependencies are inferred from the claim text.